It’s never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival

摘要: Abstract Purpose As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients quit smoking in follow-up. We evaluated whether there was survival benefit cessation after SBRT. Methods materials Patients with early-stage NSCLC treated from 2004 2013 who were still tobacco at the time of SBRT identified prospective institutional review board–approved registry. Peripheral tumors 54 Gy 3 fractions central 50 5 fractions. reviewed overall (OS) disease progression. The log-rank Cox regression tests used identify factors predictive OS. Results Thirty-two (27%) SBRT, 87 (73%) continued smoking. Median follow-up 22 months (range, 2–87). On multivariate analysis, status (hazard ratio, 2.1; 95% confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score larger tumor size worse prior number cigarette pack-years not significant ( .62). In Kaplan-Meier comparison, associated improved 2-year OS, 78% versus 69% .014). There no difference progression-free (75% vs 55%, .23) or local control (97% 88%, .63). Conclusion OS is significantly stop NSCLC, matter their previous history. Encouraging should an important part every posttreatment visit.